Table 2 Adverse event (AE; %) within placebo groups, by type of AE (where at least three reviews reported the same AE)
Amanzio, 2009 | Mahr, 2017a | Mahr, 2017b | Rief, 2006 | Rief, 2009 | Rojas-Mirquez, 2014 | Median (IQR) | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Aa | Bb | Cc | TCA | SSRI | ||||||
Abdominal pain | 2.97 | 1.04 | 1.04 | 6.8 | 3.3 | 8.4 | 9 | 5.68 | 4.5 (2.5–7.2) | |
Burning | 5.88 | 1.83 | 8.7 | 5.9 (3.9–7.3) | ||||||
Chest discomfort/pain | 0 | 0.8 | 4.2 | 0.82 | 0.8 (0.6–1.7) | |||||
Chills | 1.4 | 0.47 | 3.7 | 1.4 (0.9–2.6) | ||||||
Diarrhea | 1.25 | 3.51 | 7.7 | 3.53 | 3.5 (2.9–4.6) | |||||
Dry mouth | 4.26 | 1.75 | 3.11 | 5.1 | 19.2 | 6.4 | 4.7 (3.4–6.1) | |||
Dyspepsia | 1.13 | 1.46 | 3.21 | 3.9 | 2.03 | 2.0 (1.5–3.2) | ||||
Fatigue | 2.85 | 1.47 | 8.72 | 9.3 | 17.3 | 5.5 | 7.1 (3.5–9.2) | |||
Insomnia | 0 | 5.7 | 13.3 | 11.1 | 4.73 | 5.7 (4.7–11.1) | ||||
Paresthesia | 1.1 | 0.88 | 6.58 | 3.6 | 2.4 (1.0–4.3) | |||||
Somnolence | 1.05 | 2.76 | 5.67 | 16.8 | 6.8 | 5.44 | 5.6 (3.4–6.5) | |||
Taste disturbance | 1.06 | 1.34 | 4.1 | 1.3 (1.2–2.7) | ||||||
Vomiting/nausea | 8.9 | 4.38 | 2.11 | 7.7 | 4.9 | 2.55 | 12 | 10.5 | 8.18 | 7.7 (4.4–8.9) |
Headache | 9.9 | 10.59 | 27.4 | 19.9 | 18.01 | 18.0 (10.6–19.9) | ||||
Dizziness | 5.1 | 1.81 | 5.5 | 5.1 (3.5–5.3) | ||||||
Eye disorders | 1.4 | 6.9 | 1.2 | 1.4 (1.3–4.2) | ||||||
Constipation | 6 | 6.85 | 10.7 | 4.2 | 6.4 (5.6–7.8) | |||||